Citations

Clear

439 citation(s) found for "Stone, M".

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need
Pemmaraju, Naveen , Kantarjian, Hagop M. , Sweet, Kendra , Senapati, Jayastu , Konopleva, Marina , Frankel, Arthur E. , Gupta, Vikas , Ulrickson, Matthew L. , Gorak, Edward J., Bhatia, Sumeet, Budak-Alpdoǧan, Tülin , Mason, James R. , García‐Romero, María Teresa , López‐Santiago, Norma, Vachhani, Pankit , Lee, Sangmin , Blum, William , Walter, Roland B. , Bixby, Dale L. , Gojo, Ivana , Rampal, Raajit K. , Foran, James M. , Fathi, Amir T. , Hall, Aric C. , Jacoby, Meagan A., Mannis, Gabriel N. , Stein, Anthony S. , Rizzieri, David A. , Olin, Rebecca L. , Perl, Alexander E. , Schiller, Gary J. , Shami, Paul J. , Stone, Richard M. , Wieduwilt, Matthew J. , Vasu, Sumithira , Khoury, Joseph D. , Qazilbash, Muzaffar H. , Cuglievan, Branko , Madanat, Yazan F. , Kharfan‐Dabaja, Mohamed A. , Tallman, Martin S. , Dhakal, Prajwal , Senapati, Jayastu , Konopleva, Marina , Gupta, Vikas , Budak-Alpdogan, Tulin , Garcia-Romero, Maria Teresa , Cesarman-Maus, Gabriela , Vachhani, Pankit , Bhatt, Vijaya Raj , Walter, Roland B , Fathi, Amir T , Hall, Aric Cameron , Mims, Alice S , Rizzieri, David A , Perl, Alexander E , Strickland, Stephen Anthony , Daver, Naval , Guzmán, Mónica L. , Roboz, Gail J , Khoury, Joseph , Aung, Phyu P , Madanat, Yazan , Kharfan-Dabaja, Mohamed A , Pawlowska, Anna , Taylor, Justin , Dhakal, Prajwal , Lane, Andrew A , Kantarjian, Hagop , Wang, Eunice S. , Wilson, Nathaniel R. , Mesa, Ruben A. , Cesarman‐Maus, Gabriela , Bhatt, Vijaya Raj , Duvic, Madeleine , Lima, Marcos de , Lancet, Jeffrey E. , Daver, Naval , Ravandi, Farhad , Roboz, Gail J. , Lane, Andrew A.

Mayo Clinic

Blood | November 18, 2022 | Volume: 141 | Issue: 6 | Pages: 567-578

10.1182/blood.2022017865 | PMID 36399715 Get It

Abstract Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy with historically poor outcomes and no worldwide consensus treatment approach. Unique among most hematologic malignancies for its frequent cutaneous involvement, BPDCN can also invade other extramedullary compartments, including the central nervous system. Generally affecting older adults, many patients are unfit to receive intensive chemotherapy, and although hematopoietic stem cell transplantation is preferred for younger, fit individuals, not all are eligible. One recent therapeutic breakthrough is that all BPDCNs express CD123 (IL3Rα) and that this accessible surface marker can be pharmacologically targeted. The first-in-class agent for BPDCN, tagraxofusp, which targets CD123, was approved in December 2018 in the United States for patients with BPDCN aged ≥2 years. Despite favorable response rates in the frontline setting, many patients still relapse in the setting of monotherapy, and outcomes in patients with relapsed/refractory BPDCN remain dismal. Therefore, novel approaches targeting both CD123 and other targets are actively being investigated. To begin to formally address the state of the field, we formed a new collaborative initiative, the North American BPDCN Consortium (NABC). This group of experts, which includes a multidisciplinary panel of hematologists/oncologists, hematopoietic stem cell transplant physicians, pathologists, dermatologists, and pediatric oncologists, was tasked with defining the current standard of care in the field and identifying the most important research questions and future directions in BPDCN. The position findings of the NABC’s inaugural meetings are presented herein.
Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemia
Advani, Anjali S. , Moseley, Anna , O’Dwyer, Kristen M. , Wood, Brent L. , Park, Jae H. , Wieduwilt, Matthew J. , Jeyakumar, Deepa , Yaghmour, George , Gerds, Aaron T. , Litzow, Mark R. , Stone, Richard M. , Gerds, Aaron T , Litzow, Mark R. , Sharon, Elad , Erba, Harry Paul , Advani, Anjali S , Wood, Brent L , O'Dwyer, Kristin , Atallah, Ehab , O’Brien, Susan , Liesveld, Jane L. , Othus, Megan , Sharon, Elad

Mayo Clinic

Blood Advances | November 2, 2022 | Volume: 7 | Issue: 7 | Pages: 1279-1285

10.1182/bloodadvances.2022008216 | PMID 36322825 Get It

Abstract Novel treatment strategies are needed for the treatment of Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL) in older patients. This trial evaluated the feasibility and outcomes with the anti-CD19 bispecific T-cell–engaging antibody, blinatumomab, in combination with dasatinib and steroids. Patients 65 years of age or older with Ph+ or Ph-like ALL (with dasatinib-sensitive fusions/mutations) were eligible and could be newly diagnosed or relapsed/refractory. Induction therapy consisted of dasatinib/prednisone. Patients not achieving response by day 56 proceeded to blinatumomab reinduction therapy. Patients achieving response with induction or reinduction therapy proceeded to blinatumomab/dasatinib postremission therapy for 3 cycles followed by dasatinib/prednisone maintenance. All patients received central nervous system prophylaxis with intrathecal methotrexate for a total of 8 doses. Response was assessed at days 28, 56, and 84 and at additional time points based on response parameters. Measurable residual disease was assessed centrally by 8-color flow cytometry at day 28. A total of 24 eligible patients with newly diagnosed Ph+ ALL were enrolled with a median age of 73 years (range, 65-87 years). This combination was safe and feasible. With a median of 2.7 years of follow-up, 3-year overall survival and disease-free survival were 87% (95% confidence interval [CI], 64-96) and 77% (95% CI, 54-90), respectively. Although longer follow-up is needed, these results are encouraging, and future trials are building on this backbone regimen. This trial was registered at www.clinicaltrials.gov as #NCT02143414.
Autoreactive Plasmablasts After B Cell Depletion With Rituximab and Relapses in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
Berti, Alvise , Hillion, Sophie , Konig, Maximilian F. , Moura, Marta Casal , Hummel, Amber M., Carmona, Eva M. , Peikert, Tobias, Kallenberg, Cees G. M., Langford, Carol A. , Brunetta, Paul , Clair, E. William St. , Harris, Kristina M. , Stone, John H. , Grandi, Guido, Carmona, Eva, Monach, Paul A , Spiera, Robert F , Stone, John H , Pers, Jacques-Olivier , Specks, Ulrich , Cornec, Divi , Carmona, Eva M , Casal Moura, Marta , Berti, Alvise , Fervenza, Fernando C. , Merkel, Peter A. , Monach, Paul A. , Seo, Philip , Spiera, Robert , Grandi, Guido, Specks, Ulrich

Mayo Clinic

Arthritis & Rheumatology | October 25, 2022 | Volume: 75 | Issue: 5 | Pages: 736-747

10.1002/art.42388 | PMID 36281741 Get It

ObjectiveAutoreactive B cells are responsible for antineutrophil cytoplasmic antibody (ANCA) production in ANCA‐associated vasculitis (AAV). Rituximab (RTX) depletes circulating B cells, including autoreactive B cells. We aimed to evaluate changes and associations with relapse of the circulating autoreactive B cell pool following therapeutic B cell depletion in AAV.MethodsSequential flow cytometry was performed on 148 samples of peripheral blood mononuclear cells from 23 patients with proteinase 3 (PR3)–ANCA–positive AAV who were treated with RTX for remission induction and monitored after stopping therapy during long‐term follow‐up in a prospective clinical trial. PR3 was used as a ligand to target autoreactive PR3‐specific (PR3+) B cells. B cell recurrence was considered as the first blood sample with ≥10 B cells/μl after RTX treatment.ResultsAt B cell recurrence, PR3+ B cell frequency among B cells was higher than baseline (P < 0.01). Within both PR3+ and total B cells, frequencies of transitional and naive subsets were higher at B cell recurrence than at baseline, while memory subsets were lower (P < 0.001 for all comparisons). At B cell recurrence, frequencies of B cells and subsets did not differ between patients who experienced relapse and patients who remained in remission. In contrast, the plasmablast frequency within the PR3+ B cell pool was higher in patients who experienced relapse and associated with a shorter time to relapse. Frequencies of PR3+ plasmablasts higher than baseline were more likely to be found in patients who experienced relapse within the following 12 months compared to those in sustained remission (P < 0.05).ConclusionThe composition of the autoreactive B cell pool varies significantly following RTX treatment in AAV, and early plasmablast enrichment within the autoreactive pool is associated with future relapses.
The impact of early PEG-asparaginase discontinuation in young adults with ALL: a post hoc analysis of the CALGB 10403 study
Aldoss, Ibrahim , Yin, Jun , Wall, Anna, Mrózek, Krzysztof , Liedtke, Michaela , Claxton, David F. , Appelbaum, Frederick R. , Erba, Harry P. , Litzow, Mark R. , Tallman, Martin S. , Stone, Richard M. , Luger, Selina M. , Erba, Harry Paul , Litzow, Mark R. , Larson, Richard A , Advani, Anjali S , Claxton, David F , Aldoss, Ibrahim , Foster, Matthew C , Larson, Richard A. , Advani, Anjali S. , Stock, Wendy

Mayo Clinic

Blood Advances | October 21, 2022 | Volume: 7 | Issue: 2 | Pages: 196-204

10.1182/bloodadvances.2022007791 | PMID 36269846 Get It

Abstract Asparaginase is a key component of pediatric-inspired regimens in young adults with acute lymphoblastic leukemia (ALL). Truncation of asparaginase therapy is linked to inferior outcomes in children with ALL. However, a similar correlation in adults is lacking. Here, we studied the prevalence and risk factors associated with pegylated (PEG)-asparaginase discontinuation in young adults with ALL treated on the US intergroup Cancer and Leukemia Group B (CALGB) 10403 study and examined the prognostic impact of early discontinuation (ED) (defined as &lt;4 of 5 or 6 planned doses) on survival outcomes. The analysis included 176 patients who achieved complete remission and initiated the delayed intensification (DI) cycle. The median number of PEG-asparaginase doses administered before DI was 5 (range, 1-6), with 57 (32%) patients with ED. The ED patients were older (median, 26 vs 23 years; P = .023). Survival was apparently lower for ED patients compared with those receiving ≥4 doses, but this finding was not statistically significant (hazard ratio [HR], 1.82; 95% confidence interval [CI], 0.97-3.43; P = .06), with corresponding 5-year overall survival (OS) rates of 66% and 80%, respectively. In patients with standard-risk ALL, the ED of PEG-asparaginase adversely influenced OS (HR, 2.3; 95% CI, 1.02-5.22; P = .04) with a trend toward inferior event-free survival (EFS) (HR, 1.84; 95% CI, 0.92-3.67; P = .08). In contrast, there was no impact of early PEG-asparaginase discontinuation on OS (P = .64) or EFS (P = .32) in patients with high-risk disease based on the presence of high-risk cytogenetics, Ph-like genotype, and/or high white blood cell count at presentation. In conclusion, early PEG-asparaginase discontinuation is common in young adults with ALL and may adversely impact survival of patients with standard-risk ALL.
In Vivo Prediction of Kidney Stone Fragility Using Radiomics-Based Regression Models
Pillai, Parvathy Sudhir , Hsieh, Scott S. , Vercnocke, Andrew J. , Potretzke, Aaron M. , Koo, Kevin , Ferrero, Andrea , Sudhir Pillai, Parvathy, McCollough, Cynthia H.

Mayo Clinic

Journal of Endourology | October 7, 2022 | Volume: 37 | Issue: 4 | Pages: 443-452

10.1089/end.2022.0483 | PMID 36205579 Get It

Introduction: The surgical technique for urinary stone removal is partly influenced by its fragility, as prognosticated by the clinician. This feasibility study aims to develop a linear regression model from CT-based radiomic markers to predict kidney stone comminution time in vivo with two ultrasonic lithotrites. Materials and Methods: Patients identified by urologists at our institution as eligible candidates for percutaneous nephrolithotomy were prospectively enrolled. The active engagement time of the lithotrite in breaking the stone during surgery denoted the comminution time of each stone. The comminution rate was computed as the stone volume disintegrated per minute. Stones were grouped into three fragility classes (fragile, moderate, hard), based on inverse of the comminution rates with respect to the mean. Multivariable linear regression models were trained with radiomic features extracted from clinical CT images to predict comminution times in vivo . The model with the least root mean squared error (RMSE) on comminution times and the fewest misclassification of fragility was finally selected. Results: Twenty-eight patients with 31 stones in total were included in this study. Stones in the cohort averaged 1557 (±2472) mm 3 in volume and 5.3 (±7.4) minutes in comminution time. Ten stones had nonmoderate fragility. Linear regression of stone volume alone predicted comminution time with an RMSE of 6.8 minutes and missed all 10 stones with nonmoderate fragility. A fragility model that included stone volume, internal morphology, shape-based radiomics, and device type improved RMSE to below 3.3 minutes and correctly classified 20/21 moderate and 6/10 nonmoderate stones. Conclusions: CT metrics-based fragility models may provide information to surgeons regarding kidney stone fragility and facilitate the selection of stone removal procedures.
Temporal association between invasive procedures and infective endocarditis
Thornhill, Martin H. , Crum, Annabel , Campbell, Richard , Stone, Tony , Lee, Ellen , Bradburn, Mike , Fibisan, Veronica , Dayer, Mark , Prendergast, Bernard , Lockhart, Peter B. , Nicoll, Jon, Prendergast, Bernard D , Baddour, Larry , Thornhill, M H , Dayer, Mark J , Baddour, Larry M. , Stone, Tony

Mayo Clinic

Heart | September 22, 2022 | Volume: 109 | Issue: 3 | Pages: 223-231

10.1136/heartjnl-2022-321519 | PMID 36137742 Get It

Objective Antibiotic prophylaxis has been recommended for patients at increased risk of infective endocarditis (IE) undergoing specific invasive procedures (IPs) despite a lack of data supporting its use. Therefore, antibiotic prophylaxis recommendations ceased in the mid-2000s for all but those at high IE risk undergoing invasive dental procedures. We aimed to quantify any association between IPs and IE. Methods All 14 731 IE hospital admissions in England between April 2010 and March 2016 were identified from national admissions data, and medical records were searched for IP performed during the 15-month period before IE admission. We compared the incidence of IP during the 3 months immediately before IE admission (case period) with the incidence during the preceding 12 months (control period) to determine whether the odds of developing IE were increased in the 3 months after certain IP. Results The odds of IE were increased following permanent pacemaker and defibrillator implantation (OR 1.54, 95% CI 1.27 to 1.85, p<0.001), extractions/surgical tooth removal (OR 2.14, 95% CI 1.22 to 3.76, p=0.047), upper (OR 1.58, 95% CI 1.34 to 1.85, p<0.001) and lower gastrointestinal endoscopy (OR 1.66, 95% CI 1.35 to 2.04, p<0.001) and bone marrow biopsy (OR 1.76, 95% CI 1.16 to 2.69, p=0.039). Using an alternative analysis, bronchoscopy (OR 1.33, 95% CI 1.06 to 1.68, p=0.049) and blood transfusions/red cell/plasma exchange (OR 1.2, 95% CI 1.07 to 1.35, p=0.012) were also associated with IE. Conclusions This study identifies a significant association between specific IPs (permanent pacemaker and defibrillator implantation, dental extraction, gastrointestinal endoscopy and bronchoscopy) and subsequent IE that warrants re-evaluation of current antibiotic prophylaxis recommendations to prevent IE in high IE risk individuals.
Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia
Duncavage, Eric J., Bagg, Adam , Hasserjian, Robert P. , DiNardo, Courtney D. , Iacobucci, Ilaria , Jaiswal, Siddhartha , Vannucchi, Alessandro M. , Patel, Keyur P. , Arcila, Maria E. , Borowitz, Michael J., Cargo, Catherine , Garcia‐Manero, Guillermo , Haferlach, Torsten , Hellström‐Lindberg, Eva , Klco, Jeffery M. , Loh, Mignon Lee-Cheun, Papaemmanuil, Elli , Reiter, Andreas , Skoda, Radek C. , Solé, Françesc , Stone, Richard M. , Tefferi, Ayalew , Wu, David , Ebert, Benjamin L. , Cazzola, Mario , Godley, Lucy A , Iacobucci, Ilaria , Jaiswal, Siddhartha , Malcovati, Luca , Vannucchi, Alessandro M , Patel, Keyur P , Arber, Daniel A , Bejar, Rafael , Branford, Susan , Brown, Anna L , Döhner, Hartmut , Falini, Brunangelo , Kim, Annette S , Komrokji, Rami S , Loghavi, Sanam , Mullighan, Charles G , Ogawa, Seishi , Ross, David M , Savona, Michael R , Shimamura, Akiko , Solé, Francesc , Walter, Matthew J , Wu, David , Ebert, Benjamin L , Cazzola, Mario , DiNardo, Courtney , Godley, Lucy A. , Malcovati, Luca , Arber, Daniel A. , Berliner, Nancy , Branford, Susan , Brown, Anna , Falini, Brunangelo , Komrokji, Rami S. , Loh, Mignon L. , Loghavi, Sanam , Mullighan, Charles G. , Orazi, Attilio , Savona, Michael R.

Mayo Clinic

Blood | September 21, 2022 | Volume: 140 | Issue: 21 | Pages: 2228-2247

10.1182/blood.2022015853 | PMID 36130297 Get It

Abstract Myeloid neoplasms and acute leukemias derive from the clonal expansion of hematopoietic cells driven by somatic gene mutations. Although assessment of morphology plays a crucial role in the diagnostic evaluation of patients with these malignancies, genomic characterization has become increasingly important for accurate diagnosis, risk assessment, and therapeutic decision making. Conventional cytogenetics, a comprehensive and unbiased method for assessing chromosomal abnormalities, has been the mainstay of genomic testing over the past several decades and remains relevant today. However, more recent advances in sequencing technology have increased our ability to detect somatic mutations through the use of targeted gene panels, whole-exome sequencing, whole-genome sequencing, and whole-transcriptome sequencing or RNA sequencing. In patients with myeloid neoplasms, whole-genome sequencing represents a potential replacement for both conventional cytogenetic and sequencing approaches, providing rapid and accurate comprehensive genomic profiling. DNA sequencing methods are used not only for detecting somatically acquired gene mutations but also for identifying germline gene mutations associated with inherited predisposition to hematologic neoplasms. The 2022 International Consensus Classification of myeloid neoplasms and acute leukemias makes extensive use of genomic data. The aim of this report is to help physicians and laboratorians implement genomic testing for diagnosis, risk stratification, and clinical decision making and illustrates the potential of genomic profiling for enabling personalized medicine in patients with hematologic neoplasms.
International Consensus Statement on Obstructive Sleep Apnea
Chang, Jolie L. , Goldberg, Andrew N. , Alzoubaidi, Mohammed , Ashbrook, Liza , Auckley, Dennis , Ayappa, Indu , Bakhtiar, H., Bartley, Bethany L. , Billings, Martha E. , Boon, Maurits , Bosschieter, Pien F. N. , Braverman, Itzhak , Brodie, Kara D. , Caesar, Ray, Cahali, Michel Burihan, Cai, Yi , Cao, Michelle , Capasso, Robson , Caples, Sean M., Chang, Corissa P. , Chang, Katherine W. , Chaudhary, Nilika, Cheong, Crystal , Chowdhuri, Susmita , Cistulli, Peter A. , Claman, David M., Collen, Jacob , Coughlin, Kevin , Creamer, Jennifer , Davis, Eric M. , Dupuy-McCauley, Kara , Durr, Megan L. , Dutt, Mohan, Ali, Mazen El, Elkassabany, Nabil , Epstein, Lawrence J., Fiala, Justin A. , Freedman, Neil, Gill, Kirat, Gillespie, M. Boyd , Golisch, Lea, Gooneratne, Nalaka S., Gottlieb, Daniel J. , Green, Katherine K., Gurubhagavatula, Indira , Hayward, Nathan, Hoffmann, Oliver M. G., Holfinger, Steven , Hsia, Jennifer, Huoh, Kevin C. , Inala, Sanjana , Jobanputra, Aesha M. , Johnson, Andrew P. , Junna, Mithri R. , Kado, Jenna T. , Kaffenberger, Thomas M. , Khan, Meena , Kirsch, Douglas B. , Kominsky, Alan, Kryger, Meir H. , Kushida, Clete A. , Kuzniar, Thomas J., Lim, Diane C , Liu, Stanley Yung‐Chuan , MacKay, Stuart G. , Maurer, Joachim T. , May, Anna M. , Mitchell, Ron B. , Mullins, Anna , Nada, Eman , Naik, Sreelatha , Nokes, Brandon , Olson, Michael D. , Pang, Edward B. , Pang, Kenny P. , Perck, Eli Van de , Piccirillo, Jay F. , Pien, Grace W. , Plawecki, Andrea , Quigg, Mark , Ravesloot, Madeline J. L. , Redline, Susan , Rotenberg, Brian , Ryden, Armand, Sarmiento, Kathleen , Sbeih, Firas , Schell, Amy E., Schotland, Helena , Schwab, Richard J. , Seo, Jiyeon , Shah, Neomi , Shelgikar, Anita V., Shochat, Isaac , Soose, Ryan J. , Steele, Toby O. , Stephens, Erika M. , Stepnowsky, Carl , Thaler, Erica R. , Thapa, Sritika, Vries, Nico de, Weaver, Edward M. , Weir, Ian, Wolfe, Lisa F. , Woodson, B. Tucker , Won, Christine , Xu, Josie , Yalamanchi, Pratyusha , Yaremchuk, Kathleen , Yeghiazarians, Yerem, Yu, Jason L. , Zeidler, Michelle , Rosen, Ilene M. , Alt, Jeremiah A , Mohammed, Alzoubaidi , Ashbrook, Liza , Auckley, Dennis , Ayappa, Indu , Bartley, Bethany L , Braverman, Itzhak , Cahali, Michel B , Cai, Yi , Cheong, Crystal S J , Chowdhuri, Susmita , Cistulli, Peter A , Creamer, Jennifer , Dupuy-McCauley, Kara L , Durr, Megan L , Elkassabany, Nabil M , Fiala, Justin A , Gottlieb, Daniel J , Gulati, Arushi , Holfinger, Steven J , Huntley, Colin , Huyett, Phillip , Inala, Sanjana , Ishman, Stacey L , Jobanputra, Aesha M , Kado, Jenna T , Kezirian, Eric J , Kirsch, Douglas B , Kushida, Clete A , Lam, Derek J , Lettieri, Christopher J , Lin, Hsin-Ching , Magalang, Ulysses J , Malhotra, Atul , Mansukhani, Meghna P , Maurer, Joachim T , May, Anna M , Mitchell, Ron B , Mullins, Anna E , Nada, Eman M , Naik, Sreelatha , Nokes, Brandon T , Pack, Allan I , Pien, Grace W , Piper, Amanda J , Ravesloot, Madeline J L , Redline, Susan , Rotenberg, Brian W , Sarmiento, Kathleen F , Schmickl, Christopher N , Shelgikar, Anita Valanju , Shochat, Isaac , Soose, Ryan J , Steele, Toby O , Stephens, Erika , Strohl, Kingman P , Suurna, Maria V , Vanderveken, Olivier M , Yu, Jason L , Rosen, Ilene M , Alt, Jeremiah A. , Barrera, Jose Enrique , Cabrera‐Muffly, Cristina , Chahine, Lana M. , Hoff, Paul T. , Ishman, Stacey L. , Jella, Tarun K. , Kapur, Vishesh K. , Kezirian, Eric J. , Krystal, Andrew D. , Lam, Derek J. , Malhotra, Atul , Mansukhani, Meghna P. , Mokhlesi, Babak , Pack, Allan I , Patil, Susheel P. , Sutherland, Kate

Mayo Clinic

International Forum of Allergy & Rhinology | September 7, 2022 | Volume: 13 | Issue: 7 | Pages: 1061-1482

10.1002/alr.23079 | PMID 36068685 Get It

ABSTRACT Background Evaluation and interpretation of the literature on obstructive sleep apnea (OSA) allows for consolidation and determination of the key factors important for clinical management of the adult OSA patient. Toward this goal, an international collaborative of multidisciplinary experts in sleep apnea evaluation and treatment have produced the International Consensus statement on Obstructive Sleep Apnea (ICS:OSA). Methods Using previously defined methodology, focal topics in OSA were assigned as literature review (LR), evidence‐based review (EBR), or evidence‐based review with recommendations (EBR‐R) formats. Each topic incorporated the available and relevant evidence which was summarized and graded on study quality. Each topic and section underwent iterative review and the ICS:OSA was created and reviewed by all authors for consensus. Results The ICS:OSA addresses OSA syndrome definitions, pathophysiology, epidemiology, risk factors for disease, screening methods, diagnostic testing types, multiple treatment modalities, and effects of OSA treatment on multiple OSA‐associated comorbidities. Specific focus on outcomes with positive airway pressure (PAP) and surgical treatments were evaluated. Conclusion This review of the literature consolidates the available knowledge and identifies the limitations of the current evidence on OSA. This effort aims to create a resource for OSA evidence‐based practice and identify future research needs. Knowledge gaps and research opportunities include improving the metrics of OSA disease, determining the optimal OSA screening paradigms, developing strategies for PAP adherence and longitudinal care, enhancing selection of PAP alternatives and surgery, understanding health risk outcomes, and translating evidence into individualized approaches to therapy.
Differences of Uric Acid Transporters Carrying Extracellular Vesicles in the Urine from Uric Acid and Calcium Stone Formers and Non-Stone Formers
Lin, Zhijian , Jayachandran, Muthuvel , Haskic, Zejfa , Kumar, Sanjay , Lieske, John C. , Lieske, John C , Kumar, Sanjay

Mayo Clinic

International Journal of Molecular Sciences | September 6, 2022 | Volume: 23 | Issue: 17 | Pages: 10010

10.3390/ijms231710010 | PMID 36077407 Get It

Background: Low urine pH and volume are established risk factors for uric acid (UA) stone disease (UASD). Renal tubular epithelial cells exposed to an acidic pH and/or UA crystals can shed extracellular vesicles (EVs) into the tubular fluid, and these EVs may be a pathogenic biomarker of UASD. Methods: Urinary EVs bearing UA transporters (SLC2A9, SLC17A3, SLC22A12, SLC5A8, ABCG2, and ZNF365) were quantified in urine from UA stone formers (UASFs), calcium stone formers (CSFs), and age-/sex-matched non-stone formers (NSFs) using a standardized and published method of digital flow cytometry. Results: Urinary pH was lower (p < 0.05) and serum and urinary UA were greater (p < 0.05) in UASFs compared with NSFs. Urinary EVs carrying SLC17A3 and SLC5A8 were lower (p < 0.05) in UASFs compared with NSFs. Urinary EVs bearing SLC2A9, SLC22A12, SLC5A8, ABCG2, and ZNF365 were lower (p < 0.05) in CSFs than UASFs, while excretion of SLC17A3-bearing EVs did not differ between groups. Conclusion: EVs bearing specific UA transporters might contribute to the pathogenesis of UASD and represent non-invasive pathogenic biomarkers for calcium and UA stone risk.